<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019669</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066961</org_study_id>
    <secondary_id>NCI-99-C-0044</secondary_id>
    <secondary_id>NCI-T98-0088</secondary_id>
    <nct_id>NCT00019669</nct_id>
    <nct_alias>NCT00001800</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Immunization of Patients With Metastatic Melanoma Using a Recombinant Fowlpox Virus Encoding a GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not&#xD;
      yet known whether combining melanoma vaccine with interleukin-2 is more effective than&#xD;
      vaccine therapy alone in treating metastatic melanoma.&#xD;
&#xD;
      PURPOSE: Phase II trial to compare the effectiveness of melanoma vaccine and interleukin-2&#xD;
      with that of melanoma vaccine alone in treating patients who have metastatic melanoma that&#xD;
      has not responded to previous treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the clinical response in patients with metastatic melanoma treated with&#xD;
           immunization with recombinant fowlpox vaccine administered either intravenously or&#xD;
           intramuscularly, with or without interleukin-2 (IL-2).&#xD;
&#xD;
        -  Compare the immune response in patients before and after treatment with these regimens.&#xD;
&#xD;
        -  Compare the toxicity profile of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a partially randomized study. Patients are randomized to 1 of 3 treatment&#xD;
      cohorts.&#xD;
&#xD;
        -  Cohort 1: Patients receive recombinant fowlpox virus encoding gp100 peptide (fowlpox&#xD;
           vaccine) IV once every 4 weeks for up to 4 doses. (Closed to accrual as of 6/21/02.)&#xD;
&#xD;
        -  Cohort 2: Patients receive fowlpox vaccine intramuscularly (IM) once every 4 weeks for&#xD;
           up to 4 doses. (Closed to accrual as of 6/21/04.)&#xD;
&#xD;
        -  Cohort 3 (for patients in need of immediate interleukin-2 [IL-2] and those with disease&#xD;
           progression after treatment in cohorts 1 or 2): Patients receive fowlpox vaccine either&#xD;
           IV or IM* once every 4 weeks for 4 doses and IL-2 IV every 8 hours for a maximum of 12&#xD;
           doses beginning 24 hours after fowlpox vaccine.&#xD;
&#xD;
      NOTE: *The IM route of administration was selected as the preferred route of administration&#xD;
      from cohorts 1 and 2&#xD;
&#xD;
        -  Expanded cohort 2 (open to accrual 7/19/02): Patients receive fowlpox vaccine IM once&#xD;
           every 4 weeks for up to 4 doses. Upon disease progression, patients receive fowlpox&#xD;
           vaccine as above and IL-2 IV every 8 hours for a maximum of 12 doses beginning 24 hours&#xD;
           after fowlpox vaccine. (Closed to accrual 12/4/03.) In all cohorts, 3-4 weeks after the&#xD;
           last injection, patients achieving a complete remission may receive a maximum of an&#xD;
           additional 2 courses of therapy. Patients with responding disease may receive repeat&#xD;
           vaccinations for up to 8 courses. Patients with no response or progressive disease in&#xD;
           cohorts not receiving IL-2 may be treated with fowlpox vaccine and IL-2 as in cohort 3.&#xD;
           Patients who are randomized to receive IL-2 may not receive additional IL-2 therapy.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 84 patients (24 in cohorts 1 and 2, 19-33 in cohort 3, and 27&#xD;
      in expanded cohort 2) will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>fowlpox virus vaccine vector</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100 antigen</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven metastatic melanoma that has failed standard treatment&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  HLA-A-201 positive&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 90,000/mm^3&#xD;
&#xD;
          -  No coagulation disorders&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin ≤ 1.6 mg/dL (less than 3.0 mg/dL for patients with Gilbert's syndrome)&#xD;
&#xD;
          -  AST/ALT &lt; 2 times normal&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No major cardiovascular disease&#xD;
&#xD;
          -  No cardiac ischemia by a stress thallium test or other comparable test*&#xD;
&#xD;
          -  No myocardial infarction*&#xD;
&#xD;
          -  No cardiac arrhythmias* NOTE: *In order to be eligible to receive interleukin-2 (IL-2)&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No major respiratory disease&#xD;
&#xD;
          -  No obstructive or restrictive pulmonary disease* NOTE: *In order to be eligible to&#xD;
             receive IL-2&#xD;
&#xD;
        Immunologic:&#xD;
&#xD;
          -  No autoimmune disease&#xD;
&#xD;
          -  No known immunodeficiency disease&#xD;
&#xD;
          -  No primary or secondary immunodeficiency&#xD;
&#xD;
          -  No allergy to eggs&#xD;
&#xD;
          -  No active systemic infections&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other active major medical illness* NOTE: *In order to be eligible to receive IL-2&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior gp100 vaccination&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Prior surgery for the malignancy allowed&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 3 weeks since other prior therapy for the malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, White DE. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 2003 Aug 1;9(8):2973-80.</citation>
    <PMID>12912944</PMID>
  </reference>
  <verification_date>August 2004</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

